Topic Hub
14 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 14 of 14 clinical reviews.
A clinician-reviewed guide for caregivers administering Farxiga (dapagliflozin) to adolescents ages 12 to 17 with type 1 or type 2 diabetes, covering dosing, safety monitoring, sick-day rules, and when to call the prescriber.
Read clinical reviewA physician-reviewed guide to how dapagliflozin (Farxiga) affects growth, bone, kidney, metabolic, and pubertal development in adolescents aged 12 to 17, with clinical trial data, dosing guidance, and monitoring protocols.
Read clinical reviewA comprehensive clinical review of off-label dapagliflozin use in adolescents ages 12 to 17, covering the evidence base, dosing, safety signals, and how prescribers are applying this SGLT2 inhibitor in pediatric type 2 diabetes and beyond.
Read clinical reviewA clinician-reviewed guide to dapagliflozin (Farxiga) use in geriatric patients: efficacy, safety, dosing considerations, and trial data for adults 65 and older with type 2 diabetes, heart failure, or CKD.
Read clinical reviewFarxiga is not approved for children under 12. Learn what that means for caregivers, what evidence exists, and what approved alternatives look like for pediatric CKD and type 1 diabetes management.
Read clinical reviewA clinical review of dapagliflozin (Farxiga) safety, efficacy, and developmental concerns in pediatric patients under age 12, including current FDA approval status, renal physiology, growth effects, and prescribing guidance.
Read clinical reviewA clinical guide for parents, school nurses, and pediatric care teams on managing dapagliflozin (Farxiga) in children under 12, covering hypoglycemia risk, DKA warning signs, PE class, hydration, and 504 Plan documentation.
Read clinical reviewA comprehensive clinical guide covering dapagliflozin use in pediatric patients under age 12, current FDA approval status, and how to plan a safe, structured transition to adult endocrine and cardiology care.
Read clinical reviewA clinician-facing review of off-label dapagliflozin use in children under 12, covering the pharmacology, available trial data, dosing considerations, and current guideline positions.
Read clinical reviewA clinician-reviewed guide to using dapagliflozin in adults 65 and older, covering dose adjustments, kidney and cardiovascular safety, polypharmacy risks, and how to manage the transition from younger-adult protocols.
Read clinical reviewEverything clinicians and patients need to know about transitioning adolescents aged 12 to 17 from pediatric to adult care while continuing dapagliflozin (Farxiga) for type 1 or type 2 diabetes.
Read clinical reviewA clinician-reviewed guide for teens aged 12-17 taking dapagliflozin (Farxiga) covering hydration, gym class, field trips, cafeteria nutrition, DKA warning signs, and how to talk to school nurses.
Read clinical reviewComplete caregiver guide to administering Farxiga (dapagliflozin) to adults aged 65 and older: dosing, timing, fall and dehydration risks, renal monitoring, and when to call the prescriber.
Read clinical reviewA clinician-reviewed guide to dapagliflozin (Farxiga) use in adults 65 and older, covering physical activity safety, fall risk, hydration, dosing, and practical monitoring strategies for active older adults.
Read clinical review